Signaling crosstalk angiotensin II receptor subtypes and insulin

Endocrine Journal

Volumn 53, Issue 1, 2006, Pages 1-5

  Horiuchi, Masatsugu ^a   Mogi, Masaki ^a   Iwai, Masaru ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Diabetes; Hypertension; Insulin

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LOSARTAN; RECEPTOR SUBTYPE; VALSARTAN;

ADIPOSE TISSUE; BLOOD FLOW; CLINICAL TRIAL; CORRELATION ANALYSIS; DATA ANALYSIS; DIABETES MELLITUS; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEDICAL INFORMATICS; NONHUMAN; OBESITY; PERIPHERAL VASCULAR DISEASE; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; MICE; MODELS, ANIMAL; RATS; RECEPTOR CROSS-TALK; RECEPTORS, ANGIOTENSIN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 33645006686     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.53.1     Document Type: Review

References (24)

1. Velloso LA, Folli F, Sun XJ, White F, Saad MJA, Kahn CR (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93: 12490-12495.
2. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Invest 100: 2158-2169.
3. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472.
4. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022-2031.
5. Olsen MH, Fossum E, Hoieggen A, Wachtell K, Hjerkinn E, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S (2005) Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 23: 891-898.
6. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K (2000) The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hyperten 18: 1905-1910.
7. Henriksen EJ, Jacob S, Kinnick TR, Teachey K, Krekler M (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884-890.
8. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T (2002) Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40: 872-879.
9. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M (2004) Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-1010.
10. Kashiwagi A, Shinozaki K, Nishio Y, Maegawa H, Maeno Y, Kanazawa A, Kojima H, Haneda M, Hidaka H, Yasuda H, Kikkawa R (1999). Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 277: E976-E983.
11. Brindley DN, Wang CN, Mei J, Xu J, Hanna AN (1999) Tumor necrosis factor-alpha and ceramides in insulin resistance. Lipids 34: S85-S88.
12. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M (2001) Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104: 2716-2721.
13. Sharma AM (2004) Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 44: 12-19.
14. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51: 1699-1707.
15. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M (2001) Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15: 2727-2729.
16. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23: 463-473.
17. Kamide K, Rakugi H, Nagai M, Takiuchi S, Matsukawa N, Higaki J, Kawano Y, Ogihara T, Tuck ML (2004) Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 22: 121-127.
18. Gustafsson T, Andersson P, Chen Y, Magnusson JO, Arnqvist HJ (1999) Interaction of angiotensin II and the insulin-like growth factor system in vascular smooth muscle cells. Am J Physiol 277: H499-H507.
19. Suzuki J, Iwai M, Nakagami H, Wu L, Chen R, Sugaya T, Hamada M, Hiwada K, Horiuchi M (2002) Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 106: 847-853.
20. Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J, Ide A, Tsuda M, Okumura M, Min LJ, Mogi M, Horiuchi M (2005) Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 112: 1636-1643.
21. Elbaz N, Bedecs K, Masson M, Sutren M, Strosberg AD, Nahmias C (2000) Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor. Mol Endocrinol 14: 795-804.
22. Cui TX, Nakagami H, Nahmias C, Shiuchi T, Takeda-Matsubara Y, Li JM, Wu L, Iwai M, Horiuchi M (2002) Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol 16: 2113-2123.
23. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P (1994) Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94: 2511-2515.
24. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T (1999) Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104: 925-935.